Our mission is to find common drivers for metabolic diseases to accelerate therapeutic interventions.

The Accelerating Medicines Partnership® (AMP®) Program in Common Metabolic Diseases (AMP CMD) is a collaborative partnership among government and private-sector partners that harnesses their collective capabilities, scale, and resources to therapeutically address multiple metabolic diseases that share common pathogenic drivers and overlapping molecular pathways and make them available in a precompetitive space.

Building on the successful output of AMP Program in Type 2 Diabetes, which collected predominantly genetic datasets on over 1.5 million participants, AMP CMD generates and acquires genetic, functional genomic and multi omics data to accelerate target discovery across the metabolic disease indications. The AMP CMD Knowledge Portal (CMDKP) and the AMP CMD Genome Atlas (CMDGA), the project’s open access knowledge portals, aggregate, analyze, and display summary statistics data from subjects with type 1 and type 2 diabetes, obesity, cardiovascular, kidney, and liver diseases, and related complications.

Goals

  • Expand the CMDKP by generating new and leveraging existing genetic, genomic, and biomarker data.

  • Address data gaps in metabolic diseases, including obesity, atherosclerotic cardiovascular disease and heart failure, pre-diabetes, type 2 diabetes, autoimmune diabetes, and diabetic complications, nonalcoholic steatohepatitis, chronic kidney disease ,and inflammatory drivers.

  • Evolve the AMP CMD Knowledge Portal by developing analytic and visualization tools to support integrative analysis.

  • Deliver prioritized targets for the common metabolic diseases with supporting mechanistic data.

The Foundation for the National Institutes of Health is releasing two funding opportunities for the Accelerating Medicines Partnership® in Common Metabolic Diseases. Investigators working with genetic, genomic, and other tissues/omics data, and analytic tools and methods relating to common metabolic diseases including obesity, cardiovascular and kidney diseases, NAFLD/NASH, and diabetes are encouraged to apply. The program is especially interested in datasets from non-European ancestry cohorts. Proposals are due by April 3, 2024.

RFP 5 RFP 6

Learn More FAQ’s

Need for New Approaches

Traditionally, common metabolic diseases have been targeted and treated as individual diseases. Their potential shared molecular basis represents an opportunity to treat multiple diseases simultaneously and to provide more effective treatment outcomes.

Accelerating Target Discovery

AMP CMD will apply large scale genetic, genomic, transcriptomic, proteomic, metabolomic approaches to characterize human physiology and pathophysiology at the cellular, tissue, organ and whole organism levels. The initiative will prioritize targets for metabolic diseases and develop tools to analyze links between them.

Partners

Private Sector Partners
NP-partner
NP-partner
NP-partner
NP-partner
Public Sector Partners
NP-partner

We are proud to participate in the Accelerating Medicines Partnership to help further research progress in this field through collaboration with leading industry and non-profit partners. The ability to leverage each partners’ insights and experience, along with integrating the power of human data, will help to identify and validate novel pathways and potential therapeutic targets to address unmet clinical needs.

-Narimon Honarpour, M.D., Ph.D., Vice President of Translational
nord logo

We are excited to work on this important collaboration designed to decode the complexities of common metabolic disorders that will lead to an increased understanding of the disease drivers. This public-private partnership calls for a critical mass of researchers determined to research diabetes, obesity, non-alcoholic steatohepatitis, chronic kidney and cardiovascular diseases, with the aim to expand research strengths to address the significant unmet need for patients living with these diseases.

-Karin Conde-Knape, Ph.D., Senior Vice President for Global Drug Discovery, Novo Nordisk
nord logo
Read What Our Partners Are Saying

Data Portals

AMP CMD Knowledge Portal and AMP CMD Genome Atlas

AMP CMD Knowledge Portal currently houses 368 datasets consisting of 388 traits, representing cohorts from 66 countries.

Learn more about AMP CMDKP Learn more about AMP CMDGA

News + Publications

News

November 18, 2021
The Foundation for the NIH Announces the Release of Four Open-Competition Funding Opportunities
FNIH Announcement
May 26, 2021
The Foundation for the NIH Announces a New Research Initiative to Find Integrated Treatments Across Common Metabolic Diseases
FNIH Press Release

Publications

April 4, 2023
The Type 2 Diabetes Knowledge Portal: An open access genetic resource dedicated to type 2 diabetes and related traits
Cell Metabolism
December 21, 2022
A genome-wide CRISPR screen identifies CALCOCO2 as a regulator of beta cell function influencing type 2 diabetes risk
Nature Genetics
September 6, 2022
3D chromatin maps of the human pancreas reveal lineage-specific regulatory architecture of T2D risk
Cell Metabolism
Contact
Rachel Fischer, Ph.D.

Project Manager, Metabolic Disorders

[email protected]
For more information about supporting or becoming a partner in this project, please contact
Melissa Jones Reyes, Ph.D.

Program Manager, Translational Science

[email protected]
Aimee Ahmed

Director, Strategic Alliances and Advancement

[email protected]

Donate

Donate to the FNIH today to support medical research that saves lives

Partner With Us

Work with the FNIH to accelerate medical breakthroughs for patients